Michael P. Whyte

Michael P. Whyte, MD

  • Bone and Mineral Diseases

Sees Patients For

Diagnosis and treatment of heritable disorders of bone and mineral metabolism, bone disease in adults and children, mineral disease, osteogenesis imperfecta, rickets, osteopetrosis, hypophosphatasia, hypophosphatemia, genetics, vitamin D-resistant rickets, metabolic and dysplastic bone disease in children, chondrodysplasia, pseudohypoparathyroidism, juvenile osteoporosis

Patients Seen At

Hospital Affiliations

  • Barnes-Jewish Hospital
  • Shriners Hospital for Children - St. Louis
  • St. Louis Children's Hospital

Board Certifications

  • Internal Medicine

Academic Title(s)

Professor, Medicine
Professor, Pediatrics
Professor, Genetics
Division of Bone and Mineral Diseases
Director, Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children

Languages

  • English

Education

Fellowship

1979 Bone and Mineral Metabolism, Washington University School of Medicine, St. Louis, Missouri

Clinical Associate

1976 National Institutes of Health, Bethesda, Maryland

Residency

1974 Internal Medicine, Bellevue Hospital, New York, New York

Medical Degree

1972 Downstate College of Medicine, State University Of New York, Brooklyn, New York

B.A.

1968 Chemistry, Washington Square College of Arts and Science, New York University, New York, New York

Publications & Research

Search PubMed for publications »

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

Company Name: Enobia PharmaRoyalties: $1 - $9,999Consulting/Advisory Board: $1 - $9,999Speaker Fees: $1 - $9,999Reporting Date: 05/01/2021
Company Name: Alexion PharmaRoyalties: $1 - $9,999Consulting/Advisory Board: $1 - $9,999Speaker Fees: $1 - $9,999Reporting Date: 05/01/2021